Bristol-Myers Squibb EPS - Earnings per Share 2006-2019 | BMY
Bristol-Myers Squibb annual and quarterly earnings per share history from 2006 to 2019. Earnings per share can be defined as a company's net earnings or losses attributable to common shareholders per diluted share base, which includes all convertible securities and debt, options and warrants.
- Bristol-Myers Squibb EPS for the quarter ending September 30, 2019 was $0.83, a 28.45% decline year-over-year.
- Bristol-Myers Squibb EPS for the twelve months ending September 30, 2019 was $3.45, a 283.33% increase year-over-year.
- Bristol-Myers Squibb 2018 annual EPS was $3.01, a 393.44% increase from 2017.
- Bristol-Myers Squibb 2017 annual EPS was $0.61, a 76.98% decline from 2016.
- Bristol-Myers Squibb 2016 annual EPS was $2.65, a 184.95% increase from 2015.
| Bristol-Myers Squibb Annual EPS |
| 2018 |
$3.01 |
| 2017 |
$0.61 |
| 2016 |
$2.65 |
| 2015 |
$0.93 |
| 2014 |
$1.20 |
| 2013 |
$1.54 |
| 2012 |
$1.16 |
| 2011 |
$2.16 |
| 2010 |
$1.79 |
| 2009 |
$5.34 |
| 2008 |
$2.62 |
| 2007 |
$1.09 |
| 2006 |
$0.81 |
| 2005 |
$1.52 |
| Bristol-Myers Squibb Quarterly EPS |
| Q3 2019 |
$0.83 |
| Q2 2019 |
$0.87 |
| Q1 2019 |
$1.04 |
| Q4 2018 |
$0.71 |
| Q3 2018 |
$1.16 |
| Q2 2018 |
$0.23 |
| Q1 2018 |
$0.91 |
| Q4 2017 |
$-1.40 |
| Q3 2017 |
$0.51 |
| Q2 2017 |
$0.56 |
| Q1 2017 |
$0.94 |
| Q4 2016 |
$0.53 |
| Q3 2016 |
$0.72 |
| Q2 2016 |
$0.69 |
| Q1 2016 |
$0.71 |
| Q4 2015 |
$-0.12 |
| Q3 2015 |
$0.42 |
| Q2 2015 |
$-0.08 |
| Q1 2015 |
$0.71 |
| Q4 2014 |
$0.01 |
| Q3 2014 |
$0.43 |
| Q2 2014 |
$0.20 |
| Q1 2014 |
$0.56 |
| Q4 2013 |
$0.43 |
| Q3 2013 |
$0.42 |
| Q2 2013 |
$0.32 |
| Q1 2013 |
$0.37 |
| Q4 2012 |
$0.57 |
| Q3 2012 |
$-0.43 |
| Q2 2012 |
$0.38 |
| Q1 2012 |
$0.64 |
| Q4 2011 |
$0.51 |
| Q3 2011 |
$0.56 |
| Q2 2011 |
$0.52 |
| Q1 2011 |
$0.57 |
| Q4 2010 |
$0.28 |
| Q3 2010 |
$0.55 |
| Q2 2010 |
$0.53 |
| Q1 2010 |
$0.43 |
| Q4 2009 |
$4.05 |
| Q3 2009 |
$0.48 |
| Q2 2009 |
$0.49 |
| Q1 2009 |
$0.32 |
| Q4 2008 |
$0.63 |
| Q3 2008 |
$1.28 |
| Q2 2008 |
$0.38 |
| Q1 2008 |
$0.33 |
| Q4 2007 |
$-0.05 |
| Q3 2007 |
$0.43 |
| Q2 2007 |
$0.36 |
| Q1 2007 |
$0.35 |
| Q4 2006 |
$-0.06 |
| Q3 2006 |
$0.17 |
| Q2 2006 |
$0.34 |
| Q1 2006 |
$0.36 |
| Q4 2005 |
$0.26 |
| Q3 2005 |
$0.49 |
| Q2 2005 |
$0.50 |
| Q1 2005 |
$0.27 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$99.843B |
$22.561B |
|
Bristol-Myers Squibb is a differentiated company, led by their unique BioPharma strategy that leverages the reach and resources of a major pharma company paired with the entrepreneurial spirit and agility of a biotech firm. They work every day to deliver innovative medicines for patients with serious and life-threatening diseases. Their employees around the world work together for patients - it drives everything they do. They are focused on helping millions of patients around the world in disease areas such as oncology, cardiovascular, immunoscience and fibrosis. Through their R&D organization, they have built a sustainable pipeline of potential therapies, and actively partner to access external innovation to broaden and accelerate their work.
|
